Press Releases Year All20242023202220212020201920182017201620152014 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024 Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 Mar 05, 2024
Year All20242023202220212020201920182017201620152014 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024 Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 Mar 05, 2024
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024
